|Bid price||6.25||Open price||6.75|
|Ask price||6.75||Prev close||6.50|
Register now for FREE live Plethora Solutions Holdings share prices, Plethora Solutions Holdings stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Plethora Solutions Holdings Level 2 Data, indepth research tools and investor commentary for Plethora Solutions Holdings (PLE) and other London Stock Exchange equities.
Register now for FREE Plethora Solutions Holdings share price charts
|Name||Plethora Solutions Holdings||Epic||PLE|
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB00B06GL868|
|Activites||Plethora Solutions Holdings plc is a publicly listed speciality pharmaceutical company with a portfolio of products for the treatment and management of urological disorders. Plethora's mission is to acquire, develop and market (either directly or with partners) products to bring clinical benefit to patients suffering from urological disorders. By fulfilling this mission the Company will build a profitable and sustainable business and yield value growth for shareholders. Plethora's corporate objectives will be realised through: * Licensing or selling rights to Plethora's clinical stage assets in return for milestone and royalty revenue streams ; * Building a profitable and growing, marketing and distribution subsidiary company The Urology Company whose product portfolio will be built by licensing and acquiring rights to products approved for the treatment and management of urological disorders in the UK market.||Index||n/a|
|Latest Share Price (p)||6.50||Net Gearing (%)||202.27|
|Market Capitalisation (£m)||44.25||Gross Gearing (%)||288.54|
|Shares in issue (m)||632.21||Debt Ratio||-60.70|
|P/E Ratio||-2.69||Debt-to-Equity Ratio||0.25|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||-0.53|
|Dividend Yield (%)||0.00||Price to book value||-6.50|
|Dividend cover (x)||0.00||ROCE||-5.92|
|Earning per share (p)||-2.60||EPS Growth (%)||-36.84|
|52 week high / low||21.50 / 5.63||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
|28/04/2011||PLAC||Dr Michael Wyllie||ED||333,333|
/* */ RNS Number : 6831W Plethora Solutions Holdings PLC 11 November 2014 11 November 2014 Plethora Solutions Holdings PLC ("Plethora" or the "Company") Company Update Plethora Solutions...
Plethora Solutions Holdings said it has received the 5m euros upfront payment from Recordati as per the terms of their licensing agreement for FORTACIN (PSD502). The Agreement grants Recordati the rights to commercialise FORTACIN in the European Union, along with Russia, the Commonwealth of...
Story provided by StockMarketWire.com
Register now for FREE Plethora Solutions Holdings company news
Well after all the earlier promises, now slightly overdue and the SMA chart starting to indicate a reversal of fortune I think you might be wise to buy some. Or if you hold some, top up as I've been doing lately. For those not familiar with this stock check on previous news over the last...
any one noticed this for a rise.
Register now for FREE Plethora Solutions Holdings share price discussions